Construction has begun on Project Vision, a $35m Research and Development building for Douglas Pharmaceuticals, New Zealand’s largest pharmaceutical company.
Ashton Mitchell’s association with Douglas Pharmaceuticals began more than 20 years ago, over that time we have designed many specialised environments for Douglas including laboratories, offices and pharmaceutical manufacturing facilities both here in New Zealand and in Fiji.
“Construction has begun on Project Vision, a $35m Research and Development building for Douglas Pharmaceuticals, New Zealand’s largest pharmaceutical company.”
This latest development is Douglas’s most ambitious development yet and sets the scene for future growth in their business. The new research and development building, which is linked to the existing warehouse and offices, will house 120 people over three stories with the focus in leading the development and registration of specialty generic medicines for US, EU and global markets.
A key feature of the proposed building is the ‘skybridge’, a dynamic form which functions as both internal access between buildings and screens the old warehouse behind. The external facade consists primarily of glass and solid aluminium panel fully unitized Thermosash curtain wall system, providing for efficient construction and high-quality finish of the external fabric.
“A key feature of the proposed building is the ‘skybridge’, a dynamic form which functions as both internal access between buildings and screens the old warehouse behind.”
The 4,500m² building is due for completion in 2021 and will be the largest pharmaceutical research and development facility in New Zealand and a large investment in the local economy.
Ashton Mitchell look forward to working with Douglas, the Consultant Team and Leighs Construction as Project Vision is brought to fruition over the coming 18 months.
For more information, please visit Douglas Pharmaceuticals website:
Douglas Pharmaceuticals begins work on $35m Research and Development Building
